Elixir Biotech India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -13.54%
- Profit Growth -6.24%
- Ebitda -12.82%
- Net Worth 2.72%
- Total Assets -17.34%
About Elixir Biotech India
Elixir Biotech India Private Limited (EBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 March 2009 and has a history of 15 years and ten months. Its registered office is in Gorakhpur, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shambhu Singh, Bal Gupta, and Amit Gupta serve as directors at the Company.
Company Details
-
Location
Gorakhpur, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74900UP2009PTC037038
-
Company No.
037038
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Mar 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Elixir Biotech India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Gupta
|
Director | 24-Mar-2009 | Current |
|
Shambhu Singh
|
Additional Director | 12-Mar-2012 | Current |
|
Bal Gupta
|
Director | 24-Mar-2009 | Current |
Financial Performance of Elixir Biotech India.
Elixir Biotech India Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.54% decrease. The company also saw a slight decrease in profitability, with a 6.24% decrease in profit. The company's net worth moved up by a moderate rise of 2.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elixir Biotech India?
In 2021, Elixir Biotech India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Shyamlata Commodities Private LimitedBal Gupta is a mutual person
-
Awadh Luxury Home Developers Private Limited
Amit Gupta is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elixir Biotech India?
Unlock and access historical data on people associated with Elixir Biotech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elixir Biotech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elixir Biotech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.